PHBBF (Pharmaron Beijing Co) Growth Rank: 10 (As of Sep. 22, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHBBF Pharmaron Beijing Co Ltd PHBBF
84 GF Score
Price $1.93
GF Value $1.60
! 4 Warning Signs
View Full Analysis

What is Pharmaron Beijing Co Growth Rank?

Pharmaron Beijing Co PHBBF 84 Growth Rank is 10 as of Sep. 22, 2026, which is at its 10-year median of 10.00. GuruFocus rates PHBBF with a GF Score™ of 84/100 and a GF Value™ of $1.60. The stock has 4 warning signs investors should review.

Pharmaron Beijing Co has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Pharmaron Beijing Co Growth Rank Related Terms

PHBBF vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Pharmaron Beijing Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmaron Beijing Co Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Pharmaron Beijing Co's Growth Rank falls into.


PHBBF
84GF Score
Pharmaron Beijing Co Ltd PHBBF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Pharmaron Beijing Co (PHBBF) has a Growth Rank of 10 as of Sep. 22, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Pharmaron Beijing Co and its competitors. This is near median its historical median of 10.00. Over the past decade, Pharmaron Beijing Co's Growth Rank has ranged from 5.00 to 10.00.
Is Pharmaron Beijing Co's Growth Rank too high?
Pharmaron Beijing Co's current Growth Rank of 10 is near median its 10-year median of 10.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 10.00. Overall, Pharmaron Beijing Co has a GF Score™ of 84/100, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's Growth Rank compare to VRTX and REGN?
Pharmaron Beijing Co's Growth Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Pharmaron Beijing Co's own Growth Rank has ranged from 5.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current Growth Rank is 10, which is near median its own 10-year median of 10.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Pharmaron Beijing Co (PHBBF) has a current Growth Rank of 10. The stock's GF Value™ is $1.60, compared to a current price of $1.93 — trading 20.6% above its estimated fair value. The current Growth Rank is 10, which is near median its 10-year median of 10.00. Pharmaron Beijing Co's overall GF Score™ is 84/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Pharmaron Beijing Co (PHBBF), the current Growth Rank is 10 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmaron Beijing Co (PHBBF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued. The current stock price of $1.93 is trading 20.6% above its estimated GF Value™ of $1.60.

Key valuation signals for PHBBF:

  • Growth Rank: 10 (near median its 10-year median of 10.00)
  • GF Value™: $1.60 vs. price of $1.93 (20.6% above fair value)
  • GF Score™: 84/100 with 4 warning signs

No single metric tells the full story. See the PHBBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharmaron Beijing Co Business Description

Address 6 Tai-He Road, 8th Floor, Block 1, Beijing Economic Technological Development Area, Beijing, CHN, 100176
Pharmaron Beijing Co Ltd is a China-based contract research, development, and manufacturing organization serving the life sciences industry. It provides integrated drug discovery and development services, including synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism studies. Its operating segments comprise laboratory services, CMC (small molecule CDMO) services, clinical development services, and biologics and cell and gene therapy services. Laboratory services generate the largest share of revenue. The company supports pharmaceutical and biotechnology clients worldwide across the drug discovery, preclinical, and clinical development stages, as well as commercial manufacturing. It operates research and manufacturing facilities in China, the United States, and the United Kingdom, serving customers in North America, Europe, and Asia. Revenue is primarily derived from fee-for-service research contracts and manufacturing agreements with pharmaceutical and biotech companies.
84GF Score

Get the complete analysis for PHBBF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price
$1.60
GF Value